Craniosynostoses: Clinical Trials

5 trials for Craniosynostoses, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 terminated. 5 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Terminated 5
Phase 11Terminated 1

Follow Craniosynostoses: new trials by email Literature Review of Craniosynostoses trials Research Report on Craniosynostoses

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma
Derazantinib, Derazantinib-paclitaxel-ramucirumab combination - Gastric Adenocarcinoma
Phase 1 / Phase 2TerminatedBasilea Pharmaceutica472020-10-062024-04-04
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Pemigatinib, Pembrolizumab, Gemcitabine - Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Phase 2TerminatedIncyte Corporation72020-05-142025-11-04
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Pemigatinib - Solid Tumor Malignancy
Phase 2TerminatedIncyte Corporation1112019-10-172025-11-04
Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)
Rogaratinib - Squamous-cell Non-small Cell Lung Cancer
Phase 2TerminatedSwiss Cancer Institute152019-07-252022-11-09
Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF
Brivanib, Irinotecan - Colorectal Cancer, Colorectal Adenocarcinoma
Phase 2TerminatedM.D. Anderson Cancer Center82011-08-012020-09-03

Narrower conditions

Acrocephalosyndactylia (5)  ·  Carcinoma, Transitional Cell (1)  ·  Colorectal Neoplasms (1)  ·  Neoplasm Metastasis (1)  ·  Stomach Neoplasms (1)

Broader conditions

Bone Diseases (5)  ·  Bone Diseases, Developmental (5)  ·  Congenital Abnormalities (5)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5)  ·  Craniofacial Abnormalities (5)  ·  Dysostoses (5)  ·  Limb Deformities, Congenital (5)  ·  Musculoskeletal Abnormalities (5)  ·  Musculoskeletal Diseases (5)  ·  Syndactyly (5)  ·  Synostosis (5)  ·  Neoplasms (3)  ·  Digestive System Diseases (2)  ·  Digestive System Neoplasms (2)

Interventions

pemigatinib (2)  ·  Carboplatin (1)  ·  Gemcitabine (1)  ·  Irinotecan (1)  ·  Rogaratinib (1)  ·  brivanib (1)  ·  derazantinib (1)  ·  pembrolizumab (1)

Sponsors

Incyte Corporation (2)  ·  Basilea Pharmaceutica (1)  ·  M.D. Anderson Cancer Center (1)  ·  Swiss Cancer Institute (1)

Countries

United States (4)  ·  France (3)  ·  Germany (3)  ·  Italy (3)  ·  Spain (3)  ·  United Kingdom (3)  ·  Belgium (2)  ·  Japan (2)  ·  Poland (2)  ·  South Korea (2)  ·  Switzerland (2)  ·  Argentina (1)  ·  Australia (1)  ·  Austria (1)  ·  Brazil (1)

Top investigators

Alfredo Addeo, MD (1)  ·  Luis Feliz Vinas, MD (1)  ·  Michael Overman, MD (1)  ·  Peter Langmuir, MD (1)

Results publications

PMID 38710951

NIH funding

2018 (1), 2019 (1)